On March 15, 2022 Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, reported that it will present an analysis based on the June 10th, 2021 data cut from the expansion cohort of the Company’s Phase 1 trial of upifitamab rilsodotin (UpRi) at the upcoming Society of Gynecologic Oncology Annual Meeting on Women’s Cancer being held from March 18-21, 2022 in Phoenix, Arizona (Press release, Mersana Therapeutics, MAR 15, 2022, View Source [SID1234610117]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
UpRi is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combinations starting with carboplatin. The Company plans to initiate UP-NEXT, a Phase 3 trial of UpRi monotherapy maintenance in platinum-sensitive recurrent ovarian cancer with a design informed by FDA and CHMP feedback, in the second quarter of 2022.
"The upcoming presentation at SGO will include analysis from the nearly 100 patients with ovarian cancer treated in the expansion cohort of our UpRi Phase 1 trial based on the June 10th, 2021 data cut which supported the decision to select 36 mg/m2 as the recommended Phase 2 dose for UPLIFT. The data highlight UpRi’s robust clinical activity and differentiated safety profile which further support the design of the ongoing UPLIFT registrational trial in platinum-resistant ovarian cancer," said Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics.
Details of the presentation and posters are as follows:
Oral Plenary Session Title: Updated Results from the Phase 1 Expansion Study of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Ovarian Cancer
Abstract #: 76
Date/Time: Saturday, March 19, 2022 at 11:46 am MST
Oral Presenter: Debra L. Richardson, MD
Poster Title: Optimizing the Dose of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC): Updated Analysis of a Phase 1b Expansion Study in Ovarian Cancer
Abstract #: 319
Poster Lead Author: Bradley J. Monk, MD
Poster Title: UPGRADE: Phase 1 Combination Trial of the NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) Upifitamab Rilsodotin (UpRi; XMT-1536) in Patients With Ovarian Cancer
Abstract #: 588
Poster Lead Author: Nehal Lakhani, MD, PhD
Poster Title: UPLIFT (ENGOT-ov67/GOG-3048): A Pivotal Cohort of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed Dolaflexin Antibody Drug Conjugate (ADC) in Platinum-Resistant Ovarian Cancer
Abstract #: 585
Poster Lead Author: Debra L. Richardson, MD
Additional information can be found on the SGO website.